The cosmetic and aesthetic peptide category covers compounds being studied for skin appearance and quality, hair growth and pigmentation, and skin pigmentation effects (the melanotan family). The mechanisms across this category are more diverse than in some other peptide classes — copper-binding peptides work fundamentally differently from melanocortin agonists, which work fundamentally differently from hair-loss-targeted peptides. This thread is an overview of what compounds are in this category, how they relate to each other, and what researchers are studying.
The major compounds researchers are studying.
GHK-Cu (copper peptide). A naturally-occurring tripeptide (glycine-histidine-lysine) that forms a stable complex with copper(II). It exists naturally in human plasma and concentrations decline with age. The copper-bound form is the bioactive species — uncomplexed GHK and free copper individually do not produce the same effects. The published research base covers wound healing, skin remodeling, anti-inflammatory effects, and hair follicle effects. Both topical and injected forms are studied, with topical formulations dominating the cosmetic application research.
Melanotan I and Melanotan II. Synthetic analogs of alpha-MSH (alpha-melanocyte stimulating hormone) that activate melanocortin receptors. Melanotan I (afamelanotide) is more selective for MC1R, the melanocortin receptor that drives melanin production. Melanotan II is non-selective across melanocortin receptors (MC1R, MC3R, MC4R, MC5R), which means it produces pigmentation effects via MC1R but also produces other effects via MC4R (sexual function modulation, appetite suppression) and MC3R that some researchers want and others want to avoid.
PT-141 (bremelanotide). Another melanocortin receptor agonist, more selective for MC4R. Studied for sexual function rather than pigmentation. Different research application from the melanotan compounds despite the receptor family overlap.
PTD-DBM and other hair-loss-targeted peptides. PTD-DBM is being studied as a Wnt-pathway modulator for hair growth — a different mechanism from finasteride or minoxidil. The research base is younger and the published evidence is thinner than for the established hair loss treatments. Other peptides in the hair-loss research space include thymosin beta-4 derivatives and various Wnt-pathway modulators with overlapping mechanisms.
Hair-loss adjacent: copper peptide variants targeted for scalp. Some GHK-Cu products are formulated specifically for topical scalp application with the goal of follicle stimulation. The mechanism overlaps with general GHK-Cu skin effects but the formulation considerations differ.
Collagen peptides. These are oral collagen hydrolysates marketed for skin and joint effects. Mechanistically distinct from the other peptides in this category — collagen peptides act as nutritional substrate for endogenous collagen synthesis rather than as receptor-binding signaling molecules. The research literature on oral collagen peptide effectiveness for skin endpoints is mixed; the mechanism is less direct than the marketing typically suggests.
The mechanism diversity in this category.
Unlike the GLP-1 category (where everything works through the GLP-1 receptor) or the GH peptide category (where everything is a GHRH analog or ghrelin mimetic), the cosmetic peptide category covers genuinely different mechanisms across compounds. Copper-binding tripeptides do not have receptor agonism in the conventional sense — they work through copper-mediated effects on enzymes and transcription factors. Melanocortin agonists are conventional receptor agonists at MC1R, MC3R, MC4R, or MC5R. Hair-loss peptides target Wnt pathway or other follicle-specific signaling. The Mechanism + Half-Life thread covers each of these in more depth.
Topical versus injected administration — the split this category lives with.
GHK-Cu is studied both topically (for skin and hair applications) and via injection (for systemic effects). The topical formulations dominate the cosmetic research and most of the skin literature describes topical application.
Melanotan I and II are essentially injection-only — the peptide structure and size make oral or topical absorption minimal for systemic effects. Vendors selling oral or topical melanotan are selling product that does not match what the research has investigated.
PT-141 is studied as both injection and intranasal. The intranasal route has its own bioavailability considerations.
PTD-DBM and related hair-loss peptides are typically studied as topical scalp applications.
The Mechanism + Half-Life thread covers route-of-administration considerations for each compound family.
What is being researched.
For GHK-Cu: skin remodeling and anti-aging endpoints, wound healing, hair follicle effects, anti-inflammatory effects, and the mechanism of copper-mediated transcriptional effects. The hair growth research with topical GHK-Cu has been getting more attention recently as alternative-to-finasteride research expands.
For melanotan I and II: pigmentation effects (the primary application), photoprotection effects (the proposed mechanism for skin cancer risk reduction in some populations), and the side effect profiles of the non-selective MC1R/MC3R/MC4R/MC5R agonism with melanotan II.
For PT-141: sexual function research (the primary FDA-approved application), and ongoing research on related applications.
For hair-loss peptides: comparative effectiveness against established treatments, mechanism characterization (Wnt pathway specifics), and combination protocols with conventional treatments.
For collagen peptides: skin elasticity, joint endpoints, and the more general question of whether oral collagen is mechanistically meaningful or whether the observed effects are explainable by amino acid intake alone.
Where to go next.
The deeper threads in this category cover specific compounds. The GHK-Cu skin repair thread covers the dermatological applications. The collagen peptides versus GHK-Cu thread covers the mechanism distinction. The Melanotan II tanning and side effects thread covers the pigmentation research and the non-selective receptor profile. The PTD-DBM hair loss thread covers the Wnt pathway research. The skin-or-hair priority thread is an open community discussion. The Mechanism + Half-Life thread in this Research Library covers the pharmacology in depth. The Quality + COA thread covers vendor evaluation. The Red Flags thread covers the specific scam patterns in this market.
